<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663582</url>
  </required_header>
  <id_info>
    <org_study_id>SHP633-306</org_study_id>
    <nct_id>NCT03663582</nct_id>
  </id_info>
  <brief_title>Study of Teduglutide in Japanese Participants With Short Bowel Syndrome</brief_title>
  <official_title>A 24-Week Safety, Efficacy, Pharmacokinetic Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Are Dependent on Parenteral Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this clinical study are to evaluate the safety, efficacy, and
      pharmacokinetics (PK) of teduglutide in Japanese participants with short bowel syndrome (SBS)
      who are dependent on parenteral nutrition/intravenous (PN/IV) over a 24-week treatment
      period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Actual">August 5, 2019</completion_date>
  <primary_completion_date type="Actual">August 5, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Weekly Parenteral Nutrition/Intravenous (PN/IV) Volume</measure>
    <time_frame>Baseline to each study visit until End of the treatment (Week 24)</time_frame>
    <description>Absolute change in PN/IV volume will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Change From Baseline in Weekly Parenteral Nutrition/Intravenous (PN/IV) Volume</measure>
    <time_frame>Baseline to each study visit until End of the treatment (Week 24)</time_frame>
    <description>Relative change in PN/IV volume will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieve at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Nutrition/Intravenous (PN/IV) Volume Reduction at Week 20</measure>
    <time_frame>Baseline, Week 20</time_frame>
    <description>Percentage of participants who achieve at least 20 percent (%) reduction from baseline in weekly parenteral nutrition/intravenous will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieve at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Nutrition/Intravenous (PN/IV) Volume Reduction at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Percentage of participants who achieve at least 20 percent (%) reduction from baseline in weekly parenteral nutrition/intravenous will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieve at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Nutrition/Intravenous (PN/IV)</measure>
    <time_frame>Baseline to each study visit until end of the treatment (Week 24)</time_frame>
    <description>Percentage of participants who achieve at least 20 percent (%) reduction from baseline in weekly parenteral nutrition/intravenous will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Days per Week of Parenteral Nutrition/Intravenous (PN/IV) Support</measure>
    <time_frame>Baseline to each study visit until end of the treatment (Week 24)</time_frame>
    <description>Change in days per week of PN/IV support will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Plasma Citrulline Levels</measure>
    <time_frame>Baseline to each study visit until end of the treatment (Week 24)</time_frame>
    <description>Plasma citrulline will be measured as an assessment of enterocyte mass.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Completely Wean off Parenteral Nutrition Intravenous (PN/IV) Support</measure>
    <time_frame>Week 24</time_frame>
    <description>Number of participants who completely wean off parenteral nutrition intravenous (PN/IV) support will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Zero to the Last Measurable Concentration (AUC0-t) of Teduglutide</measure>
    <time_frame>Baseline: Predose, 15, 30 minutes (m), 1, 2, 3, 4, 6, 8, 10 and 12 hours (h) post dose; Week 4 or 12: Predose, 1, 2h post dose</time_frame>
    <description>The AUC0-t of teduglutide will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Teduglutide</measure>
    <time_frame>Baseline: Predose, 15, 30m, 1, 2, 3, 4, 6, 8, 10 and 12h post dose; Week 4 or 12: Predose, 1, 2h post dose</time_frame>
    <description>The Cmax of teduglutide will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (tmax) of Teduglutide</measure>
    <time_frame>Baseline: Predose, 15, 30m, 1, 2, 3, 4, 6, 8, 10 and 12h post dose; Week 4 or 12: Predose, 1, 2h post dose</time_frame>
    <description>The tmax of teduglutide will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal-phase Half-life (t1/2) of Teduglutide</measure>
    <time_frame>Baseline: Predose, 15, 30m, 1, 2, 3, 4, 6, 8, 10 and 12h post dose; Week 4 or 12: Predose, 1, 2h post dose</time_frame>
    <description>The t1/2 of teduglutide will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance (CL/F) of Teduglutide</measure>
    <time_frame>Baseline: Predose, 15, 30m, 1, 2, 3, 4, 6, 8, 10 and 12h post dose; Week 4 or 12: Predose, 1, 2h post dose</time_frame>
    <description>The CL/F of teduglutide will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (V/F) of Teduglutide</measure>
    <time_frame>Baseline: Predose, 15, 30m, 1, 2, 3, 4, 6, 8, 10 and 12h post dose; Week 4 or 12: Predose, 1, 2h post dose</time_frame>
    <description>The V/F of teduglutide will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline to end of the study (Week 28)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. The TEAEs are defined as AEs that started or worsened on or after the date and time of the first dose of study dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>A 12-lead ECG will be performed at the study center after the participant has been resting for at least 5 minutes. Number of participants with clinically significant changes in 12-Lead Electrocardiogram (ECG) will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Blood Pressure</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Change from baseline in blood pressure will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Pulse Rate</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Change from baseline in pulse rate will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Temperature</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Change from baseline in body temperature will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Change from baseline in hemoglobin will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematocrit</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Change from baseline in hematocrit will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Serum Blood Urea Nitrogen</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Change from baseline in serum blood urea nitrogen will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Creatinine</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Change from baseline in creatinine will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Urine Sodium</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Change from baseline in urine sodium will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Report Positive Specific Antibodies to Teduglutide</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Number of participants who report positive specific antibodies to teduglutide will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in 48-Hour Urine Output</measure>
    <time_frame>Baseline to each study visit until end of the treatment (Week 24)</time_frame>
    <description>Change from baseline in urine output will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Weight</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Change from baseline in body weight will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Mass Index (BMI)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Weight and height will be combined to report BMI in kilograms per square meter (kg/m^2). Change from baseline in BMI will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Findings in Gastrointestinal (GI) Specific Tests</measure>
    <time_frame>Week 24</time_frame>
    <description>The GI specific tests includes colonoscopy or sigmoidoscopy, abdominal ultrasound, upper GI series with small bowel follow-through (UGI/SBFT).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide</intervention_name>
    <description>Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.</description>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Syringe</intervention_name>
    <description>Teduglutide will be administered using syringe. Syringe is approved for use in Japan by Pharmaceuticals and Medical Devices Agency (PMDA).</description>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Needle</intervention_name>
    <description>Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.</description>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vial Adapter for Device</intervention_name>
    <description>Vial adapter for device is approved for use in Japan by PMDA.</description>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to voluntarily provide written, signed, and informed consent to participate in
             the study.

          2. Male or female 16 years of age or older at the time of signing informed consent.

          3. Intestinal failure due to short bowel syndrome (SBS) as a result of major intestinal
             resection (example, due to injury, volvulus, vascular disease, cancer, Crohn's
             disease) that resulted in at least 12 continuous months of parenteral
             nutrition/intravenous (PN/IV) dependence at the time of informed consent.

          4. Parenteral nutrition requirement of at least 3 times per week during the week before
             the screening visit and during the 2 weeks prior to the baseline visit.

          5. Stable PN/IV requirement for at least 4 consecutive weeks immediately prior to the
             start of teduglutide treatment. Stability is defined as: a. Actual PN/IV usage is
             similar to prescribed PN/IV; b. Baseline (Visit 2) 48-hour oral fluid intake and urine
             output (I/O) volumes fall within +/- 25 percent (%) of the respective 48-hour I/O
             volumes at the last optimization visit; c. Urine output volume should NOT fall below 2
             liter (L) and should not exceed 4 L per 48 hours at the last optimization visit, the
             stabilization visit, and the baseline visit.

          6. For participants with a history of Crohn's disease, clinical remission for at least 12
             weeks prior to the baseline visit as demonstrated by clinical assessment, which may
             include procedure-based evidence of remission.

          7. Females of childbearing potential must agree to comply with the contraceptive
             requirements of the protocol.

          8. An understanding, ability, and willingness to fully comply with study procedures and
             restrictions.

        Exclusion Criteria:

          1. Participation in a clinical study using an experimental drug within 30 days or 5.5
             halflives, whichever is longer, prior to screening, or concurrent participation in any
             other clinical study.

          2. Use of glucagon-like peptide (GLP)-2 or human growth hormone or analogs of these
             hormones within the past 6 months.

          3. Use of octreotide, GLP-1 analogs, dipeptidyl peptidase-IV inhibitors, or enteral
             glutamine within 30 days.

          4. Previous use of teduglutide.

          5. Participants with active inflammatory bowel disease (IBD) or participants with IBD who
             received a change in immunosuppressant therapy (example, azathioprine, anti- tumor
             necrosis factor (TNFs)) within the past 6 months.

          6. Intestinal malabsorption due to a genetic condition, such as cystic fibrosis,
             microvillus inclusion disease, familial adenomatous polyposis, etc.

          7. Chronic intestinal pseudo-obstruction or severe dysmotility.

          8. Clinically significant intestinal stenosis or obstruction, or evidence of such on
             upper gastrointestinal (GI) series with small bowel follow-through, within the past 6
             months.

          9. Major GI surgical intervention, including bowel lengthening procedures, within the
             past 3 months (insertion of feeding tube or endoscopic procedure is allowed).

         10. Unstable cardiac disease, (example, congestive heart failure, cyanotic disease, or
             congenital heart disease).

         11. Moderate or severe renal impairment, defined as creatinine clearance less than (&lt;) 50
             millilitre (ml)/ minute (min).

         12. Currently diagnosed with cancer or a history of any cancer except surgically curative
             skin cancer within the past 5 years.

         13. Severe hepatobiliary disease including: a. Total bilirubin level greater than or equal
             to (&gt;=) 2 times the upper limit of normal (ULN); b. Aspartate aminotransferase (AST)
             &gt;=5 times ULN; c. Alanine aminotransferase (ALT) &gt;=5 times ULN.

         14. Active clinically significant pancreatic disease, including clinical signs of
             pancreatitis associated with elevations in serum amylase or lipase &gt;=2 times ULN.

         15. More than 4 SBS-related or PN/IV-related hospital admissions (example, central line
             associated bloodstream infection, bowel obstruction, severe fluid/electrolyte
             disturbances) within the past 12 months.

         16. Unscheduled hospitalization within 30 days prior to screening.

         17. Pregnant or lactating female.

         18. Any condition or circumstance that in the investigator's opinion put the participant
             at any undue risk, prevent completion of the study, or interfere with analysis of the
             study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima-ken</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital</name>
      <address>
        <city>Hyogo</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Miyagi-Ken</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Municipal Citizen's Hospital</name>
      <address>
        <city>Yokohama</city>
        <zip>240-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teduglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, â€¦).</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>July 2, 2020</submitted>
    <submission_canceled>July 9, 2020</submission_canceled>
    <submitted>July 17, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

